Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
advances in neurology
adverse drug reaction
algorithm
analgesic
aneurysm
aneurysm, intracranial
aneurysm, intracranial, delayed cerebral ischemia with
aneurysm, intracranial, treatment of
atogepant
calcitonin gene related peptide
calcitonin gene-related peptide receptor blocker
CAT scan
cerebral ischemia
children
cluster headache
complications
dementia, autoimmune
diagnostic criteria
efficacy
eletriptan
epidemiology of neurology
eptinezumab
erenumab
fremanezumab
galcanezumab
headache
headache, preventive treatment
headache, recurrent
hypotension, systemic
migraine
migraine, children
migraine, chronic
migraine, intractable
migraine, pathogenesis
migraine, prophylaxis
migraine, treatment of
monoclonal antibodies
narcotic analgesics
neurologic disease, diagnoses of
nonsteroidal anti-inflammatory drug
peptides, brain
prevention of neurologic disorders
quality of life
recurrent
review article
rimegepant
safety
serotonin agonist
serotonin antagonist
subarachnoid hemorrhage
subarachnoid hemorrhage, treatment of
sumatriptan
telcagepant
topiramate
treatment of neurologic disorder
treatment resistant
trigeminovascular system
triptans
ubrogepant
vasospasm, cerebral
Showing articles 0 to 20 of 20

Comparative Effects of Drug Interventions for the Acute Management of Migraine Episodes in Adults:Systematic Review and Network Meta-Analysis
BMJ 386:e080107, Karlsson,W.K.,et al, 2024

Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023

Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021

Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021

One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020

Migraine
NEJM 383:1866-1876, Ashina, M., 2020

Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019

Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019

Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019

Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019

Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019

Preventive Migraine Drug Approved
JAMA 320:1746, , 2018

Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018

Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018

CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017

New Drugs in Migraine Treatment and Prophylaxis: Telcagepant and Topiramate
Lancet 376:645-655, Edvinsson,L. &Linde,M., 2010

Diagnosis and Management of Migraine
BMJ 312:1279-1283, Goadsby,P.J.&Olesen,J., 1996

Effect of Calcitonin-Gene-Related Peptide in Pts with Delayed Postop Cerebral Ischaemia after Aneurysmal SAH
Europ CGRP Study Group, Lancet 339:831-8341992., , 1992

Effect of Calcitonin-Gene-Related Peptide on Postoperative Neurological Deficits after Subarachnoid Haemorrhage
Lancet 335:869-872, Johnston,F.G.,et al, 1990

Vasoactive Peptide Release in the Extracerebral Circulation of Humans During Migraine Headache
Ann Neurol 28:183-187, Goadsby,P.J.,et al, 1990



Showing articles 0 to 20 of 20